Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
ROCKVILLE, Md., Feb. 27, 2018 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Tuesday, March 6, 2018 at 4:30 p.m. ET to discuss its financial results for the quarter and full year ended December 31, 2017 and recent operational highlights.
To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international), and enter the passcode 1584469. To access a live or recorded webcast of the call, please visit the “Investors” section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
CONTACT:
Investors
Natalie Wildenradt, 646-681-8192
[email protected]
Media
Adam Pawluk, 202-591-4063
[email protected]
